2 SURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, parallel-arm, open-label, comparator-controlled study that evaluated the efficacy and safety of tirzepatide 15 mg or MTD (10 mg or 15 mg) compared with semaglutide 2.4 mg or MTD (1.7 mg or 2.4 mg) in adults with Obesity (body mass index (BMI) 30 kg/m2), or Overweight (BMI 27 kg/m2) with at least one Obesity-related complication (e.g., hypertension, dyslipidemia), excluding diabetes.** The study included a 2-week screening period
Class III recalls are the least serious
It lowers the amount of glucagon , another hormone that raises blood sugar
Accessed Janaury 14, 2025
This isn't universalcheck your specific plan
Patients taking bupropion over a period of one year lost an average of five percent of their body weight